|
|
|
|
|
|
|
M T W Th Fri |
|
2 October, 2026 |
|
|
sponsored by
|
|
|
|
Meet a Different Brand of Experts
|
| At Cambrex, our commitment to pushing the boundaries of what’s possible sets us apart as a leader in the industry. Join us in celebrating innovation, collaboration, and the relentless pursuit of scientific advancement. Watch now and see why Cambrex is your trusted partner in pharmaceutical development. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Harvard’s David Sinclair has long been on a quest to extend the healthy human lifespan. In his latest advance, a doctoral student in his lab presented data on a small-molecule cocktail that seems to turn back cells’ biological clocks. It seems to work safely in mice. But, as Ryan Cross explains, it’s still a long way from helping people. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
David Sinclair (Jemal Countess/Getty Images for TIME) |
|
|
|
by Ryan Cross
|
BOSTON— Scientists say they’ve discovered small molecules that can reprogram cells to a younger state, raising the possibility that a simple pill could one... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Eli Lilly is looking to get into the aesthetics business and acquire drugs that could treat skin aging and diseases, body shape and hair conditions... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about Regeneron. Summit Therapeutics to test cancer drug with Datroway: The biotech agreedto partner with AstraZeneca and Daiichi Sankyo on a
clinical... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
Novartis will pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to an early-stage CD19xCD3 T cell engager, which is the Chinese biotech's lead... | |
|
|
|
|
|
